5-Amino-1MQ is a small molecule that blocks an enzyme called NNMT. Researchers have linked that enzyme to fat storage, cellular energy, and aging. Almost everything known about the compound so far comes from animal and cell studies, so the human picture is still incomplete.
That gap matters. Most of what circulates online treats 5-Amino-1MQ as a proven fat-loss compound, when the strongest evidence still sits in mice. This guide walks through what it is, how it works, what the research actually shows, the open safety questions, and the difference between the oral and injectable forms people talk about.
Key Takeaways
The Short Version
5-Amino-1MQ is a small-molecule NNMT inhibitor studied for its effects on fat metabolism, NAD levels, and muscle, not a peptide despite the common label.
It works by blocking nicotinamide N-methyltransferase, which frees up more nicotinamide for NAD production and shifts cell metabolism toward energy use.
The fat-loss and muscle findings come from animal and cell research, and no published human trials have confirmed they translate.
Human safety data does not exist yet, and 5-Amino-1MQ is sold as a research compound rather than an approved dietary supplement.
What Is 5-Amino-1MQ?
5-Amino-1MQ (5-amino-1-methylquinolinium) is a synthetic small-molecule inhibitor of the enzyme nicotinamide N-methyltransferase, usually shortened to NNMT. It was developed as a research tool to study obesity and metabolic disease, not as a consumer supplement.
You’ll often see it called a peptide. That’s wrong. A peptide is a short chain of amino acids. 5-Amino-1MQ is a single small molecule with a quinolinium ring. The difference matters, because it changes how the compound is absorbed and how it acts.
NNMT sits at a key point in cell metabolism. It’s overexpressed in fat tissue, the liver, and some tumors, often in obesity and aging. That overexpression is what made it a research target. 5-Amino-1MQ is one of the better-studied molecules built to switch it off. In a 2018 study in Biochemical Pharmacology, researchers designed methylquinolinium inhibitors to cross cell membranes and shut down NNMT without hitting related enzymes.
How 5-Amino-1MQ Works in the Body
5-Amino-1MQ works by blocking NNMT, an enzyme that uses up two molecules your cells rely on for energy and repair. When NNMT is overactive, it drains both of them. Inhibiting it lets those molecules build back up.
Here’s the chain of events researchers have mapped, mostly in animal and cell models:
- NNMT normally takes nicotinamide (a form of vitamin B3) and attaches a methyl group to it, using S-adenosylmethionine (SAM) as the methyl donor.
- This locks up nicotinamide that would otherwise feed NAD production, and it spends SAM in the process.
- NAD is a cofactor your cells need for energy metabolism and for sirtuin activity, the enzymes tied to DNA repair and longevity signaling.
- Blocking NNMT preserves more nicotinamide for NAD synthesis and leaves more SAM available.
The foundational work came from a 2014 study in Nature. Researchers knocked down NNMT in the fat tissue and liver of mice. The animals were protected against diet-induced obesity, and the effect tracked with higher NAD and SAM levels and more energy burned. That study used a genetic knockdown, not a drug. But it pinned down the target that small molecules like 5-Amino-1MQ were later built to hit.
The short version of the mechanism: less NNMT activity means more NAD, more sirtuin signaling, and a metabolic tilt toward burning energy instead of storing it. Whether that plays out the same way in people is the open question
.
What the Research Shows About 5-Amino-1MQ Benefits
The benefits attached to 5-Amino-1MQ come almost entirely from animal and cell studies, with no human trials to confirm them. The findings are promising in their own context, but they describe what happens in mice and cultured cells, not in people.
It’s worth keeping that frame in mind for every claim below.
Fat Metabolism and Body Weight
The most cited finding is fat loss in obese mice. In the 2018 Biochemical Pharmacology study, diet-induced obese mice given a potent NNMT inhibitor lost body weight and white fat mass, showed smaller fat cells, and had lower plasma cholesterol. Notably, the animals ate the same amount of food, which suggests the effect came from changes in energy use rather than appetite suppression.
A later 2022 study in Scientific Reports paired the same inhibitor with a reduced-calorie diet in obese mice. The combination drove weight and fat loss faster than the diet alone, bringing the animals closer to lean controls within the study window.
Muscle and Aging
NNMT inhibition has also been studied in aged muscle. In a 2019 study in Biochemical Pharmacology, 24-month-old mice treated with an NNMT inhibitor after muscle injury showed better muscle stem cell activity, larger muscle fibers, and roughly 70% greater peak torque compared with untreated animals. The researchers tied the effect to improved NAD balance in the muscle.
This is where the longevity interest comes from. Better NAD availability and sirtuin signaling are mechanisms associated with healthy aging, though again, the muscle data is from aged mice, not older adults.
The Human Relevance Question
Human research on NNMT itself does exist, just not on the compound. A 2015 study in Diabetologia found that people with type 2 diabetes had about twice the NNMT expression in their fat tissue compared with controls, and that higher levels tracked with worse insulin sensitivity. Exercise and bariatric surgery both lowered NNMT expression.
That study makes NNMT a credible human target. It does not show that taking 5-Amino-1MQ does anything in people. No published trial has tested the compound in humans for safety or effect.
Is 5-Amino-1MQ Safe?
There’s no human safety data for 5-Amino-1MQ, so its safety profile in people is unknown. Every safety observation so far comes from animal studies, and those can’t be assumed to carry over.
What the preclinical work suggests is modestly reassuring within its limits. In the mouse obesity research, the NNMT inhibitor didn’t change food intake or produce observable adverse effects over the treatment period. But “no observable adverse effects in short-term mouse studies” is a long way from established human safety.
A few honest caveats belong here:
- The animal studies ran for weeks, not months or years, so long-term effects are unstudied.
- NNMT affects methylation and NAD pathways that feed into many other systems. The long-term effects of blocking it in humans aren’t mapped.
- Most early obesity studies used aged or male mice, and effects can differ by sex and age.
- 5-Amino-1MQ is not an approved drug or an approved dietary supplement ingredient. It’s sold and handled as a research compound.
If you encounter dosing charts or injection protocols online, understand that they’re built from anecdote and lab-use estimates, not from clinical trials that established a safe human dose. That distinction is the whole point.
5-Amino-1MQ Oral vs Injection: What’s the Difference?
The oral and injectable forms differ mainly in how the compound reaches the bloodstream, and neither route has validated human dosing. The two are discussed at wildly different dose ranges, which tells you how much guesswork is involved.
Online sources typically cite oral doses in the tens of milligrams and injectable doses in the hundreds of micrograms, a roughly hundredfold gap. That gap reflects assumptions about absorption, not measured human data.
| Factor | Oral (capsule) | Injectable (subcutaneous) |
|---|---|---|
| Route | Swallowed, absorbed through the gut | Injected under the skin |
| Absorption concern | First-pass metabolism in the liver may reduce how much reaches circulation | Bypasses the gut, more predictable delivery |
| Convenience | Easier, no supplies needed | Requires reconstitution and injection supplies |
| Dose discussion | Cited in milligrams | Cited in micrograms |
| Human data | None established | None established |
There’s a reason the molecule was built to be membrane-permeable. The researchers behind the 2018 work designed methylquinolinium inhibitors to pass through cell membranes. That property is part of what makes oral absorption plausible. Still, the foundational animal studies used injection, so the oral route in humans rests on inference, not direct testing.
The practical takeaway: claims that one route is clearly better for people are ahead of the evidence. The human pharmacokinetic studies, the ones that would settle absorption and dosing, haven’t been published.
Frequently Asked Questions
Is 5-Amino-1MQ a peptide?
No. It’s a synthetic small molecule with a quinolinium structure. It’s frequently marketed as a peptide, but that label is inaccurate and affects how it’s absorbed and dosed.
What is 5-Amino-1MQ used for in research?
It’s used to study how blocking the NNMT enzyme affects fat metabolism, NAD levels, insulin sensitivity, and muscle in obesity and aging models. It was developed as a possible obesity and metabolic disease drug.
Are there human studies on 5-Amino-1MQ?
No published human trials exist for the compound itself. There is human research on the NNMT enzyme showing it’s elevated in type 2 diabetes, but that’s a study of the target, not the drug.
Does 5-Amino-1MQ raise NAD levels?
In animal and cell studies, inhibiting NNMT increased NAD availability. Whether oral or injectable 5-Amino-1MQ meaningfully raises NAD in humans hasn’t been tested.
Is 5-Amino-1MQ approved by the FDA?
No. It’s not an approved drug or an approved dietary supplement ingredient. It’s classified and sold as a research compound.
Where This Leaves You
5-Amino-1MQ sits in an unusual spot: a clean mechanism, encouraging animal data, and a credible human target in NNMT, paired with zero human trials. That mix is why it deserves curiosity and caution in equal measure.
At BioLongevity, we hold research compounds like this to the same transparency standard as everything else, including third-party testing and Certificates of Analysis on what’s in the vial or capsule. If you want to understand the science before the marketing, our ingredient and longevity education library breaks down NAD, metabolic pathways, and the compounds people are asking about.
Ask a qualified clinician before starting any supplement if you are pregnant, nursing, taking medication, or managing a medical condition.
These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease.
References
[1] Kraus D, Yang Q, Kong D, et al. Nicotinamide N-methyltransferase knockdown protects against diet-induced obesity. Nature. 2014;508(7495):258-262. doi:10.1038/nature13198
[2] Neelakantan H, Vance V, Wetzel MD, et al. Selective and membrane-permeable small molecule inhibitors of nicotinamide N-methyltransferase reverse high fat diet-induced obesity in mice. Biochemical Pharmacology. 2018;147:141-152. doi:10.1016/j.bcp.2017.11.007
[3] Neelakantan H, Brightwell CR, Graber TG, et al. Small molecule nicotinamide N-methyltransferase inhibitor activates senescent muscle stem cells and improves regenerative capacity of aged skeletal muscle. Biochemical Pharmacology. 2019;163:481-492. doi:10.1016/j.bcp.2019.02.008
[4] Kannt A, Pfenninger A, Teichert L, et al. Association of nicotinamide-N-methyltransferase mRNA expression in human adipose tissue and the plasma concentration of its product, 1-methylnicotinamide, with insulin resistance. Diabetologia. 2015;58(4):799-808. doi:10.1007/s00125-014-3490-7
[5] Dimet-Wiley A, Wu Q, Wiley JT, et al. Reduced calorie diet combined with NNMT inhibition establishes a distinct microbiome in DIO mice. Scientific Reports. 2022;12(1):484. doi:10.1038/s41598-021-03670-5